

OVERVIEW

PRESS RELEASES

EVENTS & PRESENTATIONS

CORPORATE GOVERNANCE

MANAGEMENT

BOARD OF DIRECTORS

COMMITTEE COMPOSITION

CONTACT THE BOARD

FINANCIAL INFORMATION

SEC FILINGS

ANNUAL REPORTS

QUARTERLY RESULTS

STOCK INFORMATION


HISTORIC STOCK LOOKUP

INVESTMENT CALCULATOR

ANALYST COVERAGE

INVESTOR FAQs

CONTACT US



INVESTOR RELATIONS

Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure

infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

STOCK QUOTE


Price **Change** **High**

Dec 11, 2017 2:16 AM EST

[VIEW DETAILS](#)

Copyright Nasdaq. Minimum 15 minutes delayed.

STOCK CHART



PRESS RELEASES

November 29, 2017 [Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company](#)

November 13, 2017 [Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne](#)

November 06, 2017 [Melinta Therapeutics Announces Successful Completion of Merger](#)

EVENTS & PRESENTATIONS

[FILTER](#)

[RESET](#)

Nov 29, 2017

[Melinta Therapeutics, Inc. Corporate Update Call.](#)

[CLICK HERE FOR WEBCAST](#)



